Comparison of Two-Drug Regimen and Three-Drug ART for HIV

Antiretroviral Therapy Overview

Recent phase 3 clinical trials have evaluated the efficacy and safety of a novel two-drug regimen against the standard three-drug antiretroviral therapy (ART) for HIV. ART typically includes two nucleoside reverse transcriptase inhibitors (NRTIs) along with a third drug, serving as both first- and second-line treatment options for HIV patients. However, the use of NRTIs is often linked with renal, cardiovascular, and bone-related complications, leading researchers to explore safer alternatives.

Proposed Two-Drug Combination

One promising alternative involves the combination of Dolutegravir and Rilpivirine. This two-drug regimen is known for its low potential for drug-drug interactions, which may help reduce long-term adverse health effects.

The SWORD Trials

Study Design and Population

The SWORD-1 and SWORD-2 trials, published in The Lancet, focused on the efficacy and safety profile of the Dolutegravir-Rilpivirine regimen compared to the conventional three-drug ART over a 48-week period. This study represents the largest comparison of a two-drug combination versus a three-drug regimen to date. It involved 1,028 participants aged 18 or older who had been on their first or second ART regimen and maintained a stable HIV viral load for at least six months. Participants were randomly assigned to either the two-drug regimen or the standard ART for 52 weeks, with assessments conducted on day one and subsequently six or seven times during the study period.

Study Findings

Results indicated that 95% of participants in both groups maintained viral loads below the accepted threshold, demonstrating that both treatment strategies effectively suppressed the HIV virus. Adverse effects were reported in 77% of the two-drug regimen group and 71% of the ART group, including headaches, upper respiratory tract infections, diarrhea, and back pain. Furthermore, neuropsychiatric adverse effects such as insomnia, anxiety, depression, and abnormal dreams were more prevalent among participants taking the two-drug regimen. The authors noted that the ART group had more time to adapt to their treatment, potentially leading to fewer new complications.

Implications of Two-Drug Therapies

Conclusion and Future Considerations

In summary, the current study presents a viable alternative to the guideline-preferred triple-drug regimens through the use of the Dolutegravir and Rilpivirine combination. This new regimen minimizes the risks associated with major NRTI toxicities and limits drug-drug interactions. Additionally, it can be effectively formulated into a fixed-dose combination tablet. Further studies are necessary to thoroughly assess the long-term safety profile and sustained efficacy in suppressing the HIV virus. This innovative treatment approach could be particularly valuable as the HIV population ages and the need to limit drug interactions becomes increasingly important.

Author and Reference

Written by Haisam Shah, BSc
Reference: Llibre, J. M., Hung, C. C., Brinson, C., Castelli, F., Girard, P. M., Kahl, L. P., … & Underwood, M. (2018). Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. The Lancet.